NRAS and melanoma: Importantly, the Mitogen Activated Protein Kinase (MAPK) pathway has been identified as a major culprit, with BRAF V600, NRAS Q61 and NF1 mutations driving 60%, 20% and 4% of melanomas, respectively3,4.